Eating disorders Pharmaceuticals Sleep and mental health 
Psychiatric Times
JUNE 23, 2025
SHOW MORE NRx Pharmaceuticals advances NRX-100, a preservative-free ketamine, through a fast-tracked FDA review for treating suicidal depression and PTSD. Sanom/Adobestock BREAKING NEWS A new formulation of ketamine is progressing through a novel US Food and Drug Administration review pathway, announced NRx Pharmaceuticals.
Psychiatric Times
JULY 7, 2025
The top 4 disease states this quarter were schizophrenia (41.7%), major depressive disorder (25%), and treatment-resistant depression (16.7%), and suicidal depression (16.7%). Trontinemab showed significant amyloid plaque reduction in Alzheimer's, validating Brainshuttle technology and prompting a phase 3 study.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Psychiatric Times
JUNE 23, 2025
The COMP005 trial is the first phase 3 study of synthetic psilocybin, marking a milestone in psychedelic research for mental health. No unexpected safety issues or imbalance in suicidal ideation were observed between treatment and placebo groups. points (95% CI [-5.7, -1.5]) in change at the primary endpoint.
Psychiatric Times
JUNE 27, 2025
She has also served as advisory board participant for Supernus Pharmaceuticals and Axsome Therapeutics. Ms Barbee has a passion to reduce the stigma around mental health and promoting increased access to mental health care and education of both clinicians and the general public.
Psychiatric Times
JUNE 13, 2025
of patients who were prescribed antipsychotics for their psychiatric illness and had evidence of tardive dyskinesia (TD) had TD recorded properly in their electronic health records, supporting the idea that TD is often underreported and misdiagnosed and, therefore, not treated appropriately.
Psychiatric Times
JUNE 30, 2025
NRx Pharmaceuticals seeks FDA approval for NRX-100, a preservative-free ketamine for suicidal depression and PTSD, via the National Priority Voucher pathway. Compass Pathways' COMP360 psilocybin has shown significant efficacy in a phase 3 trial for treatment-resistant depression, advancing psychedelic research in mental health.
Psychiatric Times
JULY 31, 2025
Positive trial results for alixorexton and AD109 indicate promising treatments for narcolepsy and obstructive sleep apnea, respectively. TSND-201 received FDA Breakthrough Therapy designation for PTSD, demonstrating significant symptom reduction in the IMPACT-1 study. SHOW MORE Check out the pipeline updates from July!
Expert insights. Personalized for you.
Let's personalize your content